Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926165 | 0.76 | REN (0.58) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6925430 | 0.76 | REN (0.60) | REN | |
| SCHEMBL7311911 | 0.75 | REN (0.57) | REN | |
| SCHEMBL5709659 | 0.73 | REN (0.57) | REN | |
| SCHEMBL9249864 | 0.73 | REN (0.62) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5709565 | 0.73 | REN (0.62) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5709629 | 0.72 | REN (0.60) | REN | |
| SCHEMBL8368680 | 0.71 | REN (0.39) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9014804 | 0.70 | REN (1.00) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7281276 | 0.70 | REN (1.00) | RENPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| US-5314920-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-05-24 | — | — | US | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| US-5314920-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | REN 2199/4885PSEN1 5/4885PSEN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.